Generic Name and Formulations:
Aztreonam 75mg/vial; pwd for inhalation via nebulization after reconstitution; preservative-free.
Gilead Sciences, Inc.
Indications for CAYSTON:
To improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
Adults and Children:
<7yrs: not established. Use a short-acting bronchodilator 15 minutes to 4 hours before each dose; or a long-acting bronchodilator 30 minutes to 12 hours before starting therapy. >7yrs: 75mg (1 vial) by nebulization three times daily (at least 4 hours apart) for 28 days. Use Altera Nebulizer only.
Monobactam or beta-lactam allergy. FEV<25% or >75% predicted, patients colonized with Burkholderia cepacia: safety/effectiveness not established. Pregnancy (Cat.B).
Do not mix with other drugs in nebulizer.
Cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, vomiting, rash; chest tightness, bronchospasm, allergic reactions (discontinue if occurs).
To support and assist patients with cystic fibrosis contact the Cayston Access Program at (877) 7CAYSTON. Should be administered immediately after reconstitution. Do not reconstitute until ready to administer a dose.
Vials—84 (w. diluent)
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)